Soligenix, Inc. (SNGX)
NASDAQ: SNGX · Real-Time Price · USD
1.120
-0.020 (-1.75%)
At close: Apr 10, 2026, 4:00 PM EDT
1.130
+0.010 (0.89%)
After-hours: Apr 10, 2026, 7:20 PM EDT
Soligenix Employees
As of December 31, 2024, Soligenix had 16 total employees, including 14 full-time and 2 part-time employees. The number of employees increased by 1 or 6.67% compared to the previous year.
Employees
16
Change (1Y)
1
Growth (1Y)
6.67%
Revenue / Employee
n/a
Profits / Employee
-$692,524
Market Cap
11.54M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 16 | 1 | 6.67% | 14 | 2 |
| Dec 31, 2023 | 15 | 0 | - | 13 | 2 |
| Dec 31, 2022 | 15 | 0 | - | 13 | 2 |
| Dec 31, 2021 | 15 | -3 | -16.67% | 13 | 2 |
| Dec 31, 2020 | 18 | 2 | 12.50% | 17 | 1 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| CytoMed Therapeutics | 43 |
| Imunon | 25 |
| BioLineRx | 24 |
| NewcelX | 15 |
| Kiora Pharmaceuticals | 12 |
| Cellectar Biosciences | 11 |
| Traws Pharma | 7 |
| Cadrenal Therapeutics | 4 |
SNGX News
- 9 days ago - Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy - PRNewsWire
- 11 days ago - Soligenix Announces Recent Accomplishments and Year End 2025 Financial Results - PRNewsWire
- 16 days ago - Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's Disease - PRNewsWire
- 19 days ago - HyBryte™ Treatment Results to be Presented at US Cutaneous Lymphoma Consortium Annual Workshop 2026 - PRNewsWire
- 23 days ago - IBN Announces Latest Episode of The BioMedWire Podcast Featuring the Return of Dr. Christopher Schaber, CEO of Soligenix Inc. - GlobeNewsWire
- 23 days ago - Soligenix Announces HyBryte™ Clinical Summary Published in "Expert Opinion on Investigational Drugs" - PRNewsWire
- 4 weeks ago - Soligenix Announces SGX945 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency - PRNewsWire
- 6 weeks ago - Soligenix Receives Positive Opinion from the European Medicines Agency on the Request for Orphan Drug Designation for SGX945 for the Treatment of Behçet's Disease - PRNewsWire